You are here: Home » Companies » News
Business Standard

Pharma, health care sectors deliver 5-17 times returns to PE investors

Private equity (PE) major KKR India, which had bought 38 per cent stake for Rs 1,400 crore, could make 2.27 times its invested capital if the deal is valued at $1.25 billion

Topics
Pe Investors

Ranju Sarkar  |  New Delhi 

Medicine
Image via Shutterstock

Hong Kong-listed Shanghai Fosun Pharmaceutical controlled by billionaire Guo Guangchang has submitted a non-binding bid to acquire 96 per cent stake in Gland Pharma.

Private equity (PE) major KKR India, which had bought 38 per cent stake for Rs 1,400 crore, could make 2.27 times its invested capital if the deal is valued at $1.25 billion.

A Reuters report on Tuesday said Gland Pharma is valued at $1.5 billion.

CX Partners made 3.52 times returns on its investments in Thyrocare, when the PE firm divested 19 per cent stake in the company in its recent successful initial public offering (IPO). After the IPO,

CX Partners will hold 2.02 per cent in Thyrocare. Norwest Venture, Samara Capital and ICICI Bank did not sell their stake in Thyrocare.

KKR and CX Partners are not alone. PE investors have made five-17 times returns on their investments in healthcare firms and drug makers such as Intas Pharmaceuticals, Mankind Pharma, Paras Pharmaceuticals, Dr Lal PathLabs, Aster DM, Lupin and Indoco Remedies, according to Venture Intelligence.

ChrysCapital has made the best return, of 17 times its investment in Intas Pharmaceuticals and 13 times in Mankind Pharma. Sequoia Capital India has made six times and eight times on its investments in Dr Lal PathLabs and Paras Pharma. Most investors in Aster DM, Lupin, Indoco Remedies, Medreich and Cloud Nine made around five times their investments in these companies.

Pharma, health care sectors deliver 5-17 times returns to PE investors

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, May 19 2016. 00:24 IST
RECOMMENDED FOR YOU
.